REVIVE webinar in collaboration with CF AMR Syndicate.
Speakers:
- Jane Davies, Professor of Paediatric Respirology and Experimental Medicine, National Heart and Lung Institute, Imperial College London (UK)
- Neill Gingles, Lead Scientist, Medicines Discovery Catapult (UK)
- David Richards, Chief Executive Officer, Clarametyx (USA)
Moderator:
- Deborah O’Neil, Chief Executive Officer, NovaBiotics Ltd (UK)
Chronic respiratory infections remain one of the most serious and persistent challenges in the care of people with cystic fibrosis (CF), even in the era of CFTR modulator therapy . This webinar brings together clinical experts, product developers, and innovators to explore the evolving infectious disease landscape in CF—focusing on the urgent need for novel antimicrobials, prioritizing difficult to treat Pseudomonas, Burkholderia, and NTM infections. It will highlight the unmet clinical needs, examine how well-designed target product profiles (TPPs) can guide meaningful innovation, and explore real-world challenges and opportunities in antimicrobial discovery and development for the CF community.
Presentation 1: The Clinical Picture of CF Infections: Why We Need New Antimicrobials (Jane Davies)
The lives of many people with CF have improved enormously with the advent of CFTR modulator drugs. These drugs do not however eradicate chronic lung infections, which persist and cause inflammation and structural lung damage. Similarly, pulmonary exacerbations are reduced in number, but not prevented completely. Current antimicrobial drugs have not been designed with the environment of the CF airway in mind, and are only partially effective.
Presentation 2: Shaping Innovation Together: Designing and implementing Patient-Centric Target Product Profiles (TPPs) (Neill Gingles)
- Overview and mission of the CF AMR Syndicate
- Aligning the goals for drug development with the needs of people with CF – development of patient-centric TPPs
- Implementation of TPPs via the Collaborative Discovery Programme
Presentation 3: Perspectives from Innovators: Navigating the CF Drug Discovery Landscape and the unique Challenges and opportunities in CF (David Richards)
- Unique dynamics in addressing the burden of CF
- Therapeutic strategies that can intervene in multiple mechanisms
- Progress with anti-biofilm approach CMTX-101
This live webinar including an interactive Q&A session will be broadcast on 19 February 2026. You can find your timezone here.
If you have questions or comments, please let us know: revive@gardp.org.